co-diovan 8012.5 mg film coated tablets
novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 80 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension for patients in whom combination therapy is appropriate.
co-diovan 16012.5 mg film-coated tablets
novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 12.5 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.
co-diovan 16025 mg film-coated tablets
novartis israel ltd - hydrochlorothiazide; valsartan - film coated tablets - valsartan 160 mg; hydrochlorothiazide 25 mg - valsartan and diuretics - valsartan and diuretics - co-diovan is indicated for the treatment of hypertension in patients whose blood pressure is not adequately controlled by monotherapy. this fixed combination should be used as second-line therapy.
co-diovan 320/25 mg valsartan 320 mg/hydrochlorothiazide 25 mg film-coated tablet blister pack
novartis pharmaceuticals australia pty ltd - valsartan, quantity: 320 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; crospovidone; hypromellose; purified talc; iron oxide yellow; macrogol 4000; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.
co-diovan 320/12.5 mg valsartan 320 mg/hydrochlorothiazide 12.5 mg film-coated tablet blister pack
novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 320 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; crospovidone; microcrystalline cellulose; magnesium stearate; hypromellose; purified talc; iron oxide red; macrogol 4000; iron oxide black; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.
co-diovan 160/25 valsartan 160 mg and hydrochlorothiazide 25 mg tablet blister pack
novartis pharmaceuticals australia pty ltd - valsartan, quantity: 160 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; hypromellose; purified talc; iron oxide yellow; macrogol 4000; iron oxide red; iron oxide black; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.
co-diovan 160/12.5 valsartan 160 mg and hydrochlorothiazide 12.5 mg tablet blister pack
novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 160 mg - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide red; macrogol 8000; magnesium stearate; hypromellose; colloidal anhydrous silica - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.
co-diovan 80/12.5 valsartan 80 mg and hydrochlorothiazide 12.5 mg tablet blister pack
novartis pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; valsartan, quantity: 80 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; iron oxide yellow; colloidal anhydrous silica; crospovidone; purified talc; magnesium stearate; hypromellose; macrogol 8000; iron oxide red; titanium dioxide - co-diovan is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.
canvac 4 + cci combination vaccine pack
zoetis australia pty ltd - bordetella bronchiseptica (inactivated cell free extract; canine distemper virus - living; canine parainfluenza virus; canine adenovirus type 2 live (cav ii); canine parvo virus type 2 - parenteral liquid/solution/suspension - bordetella bronchiseptica (inactivated cell free extract vaccine-microbial active 0.0 qs dose; canine distemper virus - living vaccine-viral active 0.0 qs dose; canine parainfluenza virus vaccine-viral active 0.0 qs dose; canine adenovirus type 2 live (cav ii) vaccine-viral active 0.0 qs dose; canine parvo virus type 2 vaccine-viral active 0.0 qs dose - immunotherapy - dog | bitch | castrate | puppy - bordetella bronchiseptica | canine distemper | canine parvovirus | hepatitis :- infectious | parainfluenza virus type 2 (infections) | canine adenovirus type 1 | canine adenovirus type 2 | canine cough syndrome | infections caused by parainflu | infectious canine hepatitis | infectious tracheobronchitis | parvovirus
intruder insecticide
nippon soda co., ltd - acetamiprid; n-methylpyrrolidone; dimethyl sulfoxide - soluble concentrate - acetamiprid pyridine active 225.0 g/l; n-methylpyrrolidone solvent other 334.0 g/l; dimethyl sulfoxide solvent other 515.0 g/l - insecticide - cotton | potato - cotton aphid | green mirid bug | green peach aphid | melon aphid